UNCY

Unicycive Therapeutics, Inc. [UNCY] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

UNCY Stock Summary

Top 10 Correlated ETFs

UNCY


Top 10 Correlated Stocks

UNCY


In the News

07:03 28 Mar 2024 UNCY

Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting

LOS ALTOS, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that two posters related to the Company's lead product candidate, oxylanthanum carbonate (OLC), will be presented at the National Kidney Foundation Spring Clinical Meeting taking place May 14-18, 2024, in Long Beach, California.

10:40 28 Mar 2024 UNCY

Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update

Unicycive (UNCY) rises after the encouraging progress in the late-stage development of its lead candidate, OLC, for the hyperphosphatemia indication. The NDA submission is expected around mid-2024.

07:03 28 Mar 2024 UNCY

Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023

LOS ALTOS, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two upcoming investor conferences in December 2023.

07:20 28 Mar 2024 UNCY

The 7 Most Undervalued Penny Stocks to Buy in October 2023

Investing in undervalued penny stocks is always going to be about the same few things. Most investors are attempting to find cheap, short-term plays with reasonable catalysts in their favor.

09:28 28 Mar 2024 UNCY

Why Is Unicycive Therapeutics (UNCY) Down 24% Today?

Unicycive Therapeutics (NASDAQ: UNCY ) stock is falling on Friday after the medical company provided investors with an update from regulators. According to the clinical-stage biotechnology company, the FDA wants further information concerning lanthanum dioxycarbonate (LDC).

07:38 28 Mar 2024 UNCY

Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

LOS ALTOS, Calif., June 16, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced today that Company CEO, Shalabh Gupta, MD, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET 

06:00 28 Mar 2024 UNCY

Analyzing Penny Stocks After a Market Crash, 3 Tips

Use these tips for analyzing penny stocks after a market crash The post Analyzing Penny Stocks After a Market Crash, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

11:00 28 Mar 2024 UNCY

How to Identify Promising Penny Stocks: 3 Tips

Use these tips for identifying promising penny stocks The post How to Identify Promising Penny Stocks: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

06:00 28 Mar 2024 UNCY

How to Future Proof Your Penny Stocks Investing Strategy

Use these tips for future proofing your penny stocks strategy The post How to Future Proof Your Penny Stocks Investing Strategy  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

06:00 28 Mar 2024 UNCY

Penny Stocks Investing: The Pros and Cons of Day Trading

What you need to know about day trading penny stocks The post Penny Stocks Investing: The Pros and Cons of Day Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

UNCY Financial details

Company Rating
Neutral
Market Cap
51.09M
Income
-38.73M
Revenue
675K
Book val./share
0.11
Cash/share
0.44
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
29 Mar 2024
P/E
-0.84
Forward P/E
-6.59
PEG
-0.05
P/S
51.49
P/B
9.5
P/C
3.3
P/FCF
-1.74
Quick Ratio
0.93
Current Ratio
1.2
Debt / Equity
0.25
LT Debt / Equity
0.16
-
-
EPS (TTM)
-2.38
EPS next Y
-0.22
EPS next Q
-0.18
EPS this Y
31.87%
EPS next Y
-90.76%
EPS next 5Y
-116.25%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-48%
-
-
-
-
SMA20
-50%
SMA50
-
SMA100
-
Inst Own
70.03%
Inst Trans
9.93%
ROA
-199%
ROE
-763%
ROC
-4.96%
Gross Margin
100%
Oper. Margin
-2931%
Profit Margin
-5737%
Payout
-
Shs Outstand
34.75M
Shs Float
24.99M
-
-
-
-
Target Price
-
52W Range
0.47-2.287
52W High
-
52W Low
-
RSI
55
Rel Volume
0.22
Avg Volume
355.56K
Volume
76.94K
Perf Week
2.11%
Perf Month
10.69%
Perf Quarter
74.72%
Perf Half Y
137.32%
-
-
-
-
Beta
2.682
-
-
Volatility
0.05%, 0.1%
Prev Close
-0.68%
Price
1.45
Change
1.4%

UNCY Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K
Revenue per share
0000.06
Net income per share
-0.16-0.3-0.91-1.2
Operating cash flow per share
-0.08-0.17-0.49-1.04
Free cash flow per share
-0.08-0.17-0.5-1.04
Cash per share
001.420.03
Book value per share
-0.06-0.311.41-0.03
Tangible book value per share
-0.06-0.311.41-0.03
Share holders equity per share
-0.06-0.311.41-0.03
Interest debt per share
0.040.320.080.01
Market cap
72.48M42.5M24.05M8.13M
Enterprise value
72.93M45.01M7.78M7.83M
P/E ratio
-31.46-16.95-2.26-0.45
Price to sales ratio
0008.55
POCF ratio
-61.64-29.13-4.17-0.52
PFCF ratio
-61.64-29.13-4.15-0.52
P/B Ratio
-82-15.911.46-17.45
PTB ratio
-82-15.911.46-17.45
EV to sales
0008.23
Enterprise value over EBITDA
-37.15-22.28-0.87-0.43
EV to operating cash flow
-62.01-30.85-1.35-0.5
EV to free cash flow
-62.01-30.85-1.34-0.5
Earnings yield
-0.03-0.06-0.44-2.22
Free cash flow yield
-0.02-0.03-0.24-1.93
Debt to equity
-0.52-0.940.02-0.33
Debt to assets
24.2112.320.020.06
Net debt to EBITDA
-0.23-1.241.810.02
Current ratio
0.020.078.750.81
Interest coverage
-14.12-8.28-14.29-3.01K
Income quality
0.540.640.580.87
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0006.91
Research and developement to revenue
00013.08
Intangibles to total assets
0000
Capex to operating cash flow
000.010
Capex to revenue
0000
Capex to depreciation
00-2.23-0.01
Stock based compensation to revenue
0001.1
Graham number
0.471.445.380.91
ROIC
4.9314.25-0.56115.76
Return on tangible assets
-121.26-12.29-0.57-6.41
Graham Net
-0.06-0.341.23-0.19
Working capital
-884K-2.67M16.31M-640K
Tangible asset value
-884K-2.67M16.48M-466K
Net current asset value
-884K-2.67M16.15M-640K
Invested capital
-0.52-0.940.02-0.33
Average receivables
0000
Average payables
0253K463K817K
Average inventory
0000
Days sales outstanding
0000
Days payables outstanding
00270.83K46.51K
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
0000.01
Inventory turnover
0000
ROE
2.610.94-0.6438.76
Capex per share
0000

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.0600.0400
Net income per share
-0.37-0.35-1.65-0.25-0.13
Operating cash flow per share
-0.24-0.4-0.26-0.36-0.14
Free cash flow per share
-0.24-0.4-0.26-0.36-0.14
Cash per share
0.470.031.61.240.44
Book value per share
0.31-0.030.690.450.11
Tangible book value per share
0.31-0.030.690.450.11
Share holders equity per share
0.31-0.030.690.450.11
Interest debt per share
0.010.010.070.060.03
Market cap
8.89M8.13M31.99M19.5M28.06M
Enterprise value
2.07M7.88M8.65M1.62M14.59M
P/E ratio
-0.4-0.38-0.32-1.27-1.59
Price to sales ratio
9.34047.3900
POCF ratio
-2.49-1.34-8.16-3.54-6.35
PFCF ratio
-2.49-1.34-8.16-3.54-6.35
P/B Ratio
1.92-17.453.042.868.17
PTB ratio
1.92-17.453.042.868.17
EV to sales
2.18012.8100
Enterprise value over EBITDA
-0.38-1.49-2.09-0.4-2.46
EV to operating cash flow
-0.58-1.29-2.21-0.29-3.3
EV to free cash flow
-0.58-1.29-2.21-0.29-3.3
Earnings yield
-0.63-0.66-0.79-0.2-0.16
Free cash flow yield
-0.4-0.75-0.12-0.28-0.16
Debt to equity
0.04-0.430.090.140.25
Debt to assets
0.020.070.040.040.04
Net debt to EBITDA
1.240.055.634.462.27
Current ratio
1.80.811.641.421.2
Interest coverage
-1.85K-1.78K-350.17-135.06329.89
Income quality
0.641.140.271.431.02
Dividend Yield
000.0100
Payout ratio
00-0.0100
Sales general and administrative to revenue
1.7902.7400
Research and developement to revenue
5.0504.4900
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
0-0.050-0.150
Stock based compensation to revenue
0.2800.2100
Graham number
1.60.55.061.590.57
ROIC
-1.1148.44-0.58-0.5-1.13
Return on tangible assets
-0.55-1.89-0.92-0.17-0.23
Graham Net
0.1-0.190.50.18-0.05
Working capital
4.44M-640K10.21M6.51M3.11M
Tangible asset value
4.63M-466K10.52M6.83M3.43M
Net current asset value
4.41M-640K9.5M5.88M2.56M
Invested capital
0.04-0.430.090.140.25
Average receivables
00000
Average payables
1.46M1.53M728K528K718K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
199.44K38.07K1.22K514.621.13K
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
000.070.170.08
Inventory turnover
00000
ROE
-1.211.44-2.39-0.56-1.28
Capex per share
00000

UNCY Frequently Asked Questions

What is Unicycive Therapeutics, Inc. stock symbol ?

Unicycive Therapeutics, Inc. is a US stock , located in Los altos of Ca and trading under the symbol UNCY

What is Unicycive Therapeutics, Inc. stock quote today ?

Unicycive Therapeutics, Inc. stock price is $1.45 today.

Is Unicycive Therapeutics, Inc. stock public?

Yes, Unicycive Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap